Categories: India

Bharat Biotech to conduct Covaxin phase-4 trials to check real-world effectiveness

HYDERABAD: Bharat Biotech will be conducting phase-4 clinical trials of indigenously developed Covaxin to check its real-world effectiveness.
It will also apply for full licensure for Covaxin only after it gets final analysis data of phase-3 studies, the company said on Wednesday.
According to the company, the phase-4 trials will not just help check the real-world effectiveness but also ensure that “its vaccine met every rigorous scientific standard for safety, effectiveness, and manufacturing quality needed to support emergency use authorization (EUA)”.
“It is important to note, the inoculation which began in mid-January and with several million doses administered, will have credible and sizable data soon,” it said.
The Hyderabad-based vaccine maker also said that the full data of Covaxin’s phase-3 trials will first be submitted to the Central Drugs Standard Control Organisation (CDSCO), followed by peer reviewed journals and will be made public during July.
“Once data from final analysis of phase-3 studies are available, Bharat Biotech will apply for full licensure for Covaxin,” it said, adding that “Covaxin has undergone and will continue to undergo the most intensive safety and efficacy monitoring in Indian vaccines history.” As per interim data announced by Bharat Biotech and Indian Council of Medical Research (ICMR), Covaxin, which was given EUA in early January while phase-3 trials were underway, reported an overall efficacy of 78% and a 100% efficacy against hospitalisations.
The statements come in the wake of a Twitter spat between Bharat Biotech’s business development and advocacy head Raches Ella and Kolkata-based endocrinologist Dr Awadhesh Kumar Singh over the latter’s study comparing immune responses of Covaxin and Covishield, which also led to Singh and some Twitterati demanding that Bharat Biotech make Covaxin Phase-3 trials data public.
Bharat Biotech also slammed the comparative study as flawed.
“This is not a peer reviewed publication, nor statistically and scientifically designed study, the study design and conduct reflect an ad hoc analysis, rather than a predetermined hypothesis,” it said.
“Further, the study was not registered on CTRI website, nor approved by CDSCO and SEC…Factually studies involving human clinical trials and human subjects should obtain their approvals,” it added.

news2in

Share
Published by
news2in

Recent Posts

44 ordered to attack the procession

Ludhiana: The police have submitted FIR to four identified and at least 40 unknown attackers…

3 years ago

Punjab: Police Reject conspiracy theory in the case of Deep Sidhu

Sonīpat / Ludhiana / Ambala: Actor Punjabi - Activist Activist Deep Sidhu, who died in…

3 years ago

Punjab: Hidden Strength Working Behind PM Narendra Modi, Arvind Kejriwal, said Rahul Gandhi

PATIALA / MANSA / BARNALA: Attacking Prime Minister Narendra Modi and AAP National Convener Kejriawal,…

3 years ago

BJP made AAP to endanger the Congress, said Ajay

Jalandhar: BJP and AAM AAM AADMI parties are one party, Secretary General of the Ajay…

3 years ago

Our job is to make Punjab No. 1 State: Meenakshi Lekhi

Ludhiana: Minister of Union Culture Meenakshi Lekhi while campaigning to support the BJP candidate from…

3 years ago

Feb 20 is an opportunity to change the destiny of Punjab and his children: Bhagwant Mann

Machhiwara (Ludhiana): AAM AAM AADMI Party (AAP) Head of Punjab Candidate and Members of Parliament…

3 years ago